AGENCIA Inc. (Headquarters: Nagoya, Japan; CEO: Jean Pierre), a leading innovator in automotive digital transformation through artificial intelligence (AI) and 360° imaging, today announced that its proprietary SaaS platform “360°Car®” has been officially certified by GUINNESS WORLD RECORDS™ as the “Largest online album of 360° car views,” achieving an unprecedented 7,096,049 vehicle images. This press release features multimedia. View the full release here: https://www.businesswire.com/news/h...

Phenom, the leader in applied AI that helps organisations hire faster, develop better and retain longer, announced its first IAMPHENOM Europe conference — the only applied AI event for human resources in the region — is sold out. A waitlist is available on a first-come, first-serve basis. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251103977081/en/Phenom announced its first IAMPHENOM Europe conference — the only applied AI event ...

Aurigene Oncology Limited, a clinical-stage biopharmaceutical company developing novel therapies in oncology, today announced initial clinical results from 1st two cohorts of its ongoing Phase 1 clinical trial evaluating AUR112 in patients with relapsed or refractory lymphoid malignancies. Early findings show that AUR112 is safe, well tolerated, demonstrating meaningful clinical activity, with objective responses observed across multiple lymphoma subtypes, including Mantle Cell Lymphoma (MCL) a...

Luma AI, the frontier artificial intelligence company building multimodal AGI intelligence and known for its flagship product Dream Machine, today announced a major step in its global expansion with the opening of its first international office in London, UK. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251202217704/en/LUMA AI OPENS FOR INTERNATIONAL BUSINESS WITH FORMER WPP EXECUTIVE JASON DAY LEADING NEW LONDON OFFICE As creative...

AdvanCell, a clinical-stage radiopharmaceutical company developing innovative targeted alpha therapies for cancer, today announced the initiation of the TheraPb Phase 2 expansion trial (NCT05720130) evaluating its lead investigational candidate, ADVC001, in metastatic prostate cancer. The news follows the encouraging Phase 1b dose escalation results presented at the European Society for Medical Oncology (ESMO) 2025 congress that showed a favorable safety profile and compelling anti-tumor activi...